atrial fibrillation in comparison with HD patients (79 vs. 66%, p = 0.04). Conclusion: The majority of nephrologists want involvement in thrombolysis decisions relevant to their patients. Concerns about bleeding risks with thrombolysis are high and we identify a vital need to improve access to stroke rehabilitation in the UK, especially in HD patients.
functional disability compared to placebo [4] , with a low but appreciable risk of haemorrhagic transformation which increases further when given >6 h from symptom onset [5] .
To date the risks and benefits of stroke thrombolysis in dialysis patients remain undefined. Renal impairment is not a licensed contra-indication to alteplase with no trials to date exploring the effect of kidney function on outcome. Uraemia confers a bleeding diathesis which is particularly marked in patients with end-stage renal disease (ESRD) [6] . This is further accentuated with concomitant antiplatelet use, regular exposure to heparins during haemodialysis (HD) and the effects of hypertension and hypervolaemia. It can therefore be hypothesised that the haemorrhagic risk of thrombolysis may outweigh any benefits. This concerned the majority of stroke experts polled in the only previous survey conducted on this topic [7] .
The opinions and experience of nephrologists or kidney patients have never been solicited to date. Furthermore no study has explored the current clinical practice in acute stroke management for patients on peritoneal dialysis (PD) as well as those receiving HD. We therefore sought to comprehensively ascertain the opinions of nephrologists on acute stroke management and thrombolysis in the dialysis cohorts under their care.
Methods
Nephrology services across the UK are delivered by large renal units, some with and some without transplantation programmes. At the time of this survey, 72 renal units (23 with transplantation) covered the population of the UK staffed by approximately 460 consultant renal physicians. We contacted all consultant nephrologists within the UK by e-mail to participate anonymously in an internet-based survey. A second invitation was sent to clinicians who had not responded to the initial e-mail within 2 weeks, and all responses were evaluated 1 month after the initial request.
We aimed to capture opinions on a number of facets of care around stroke thrombolysis including the role of nephrologists in the decision-making process, areas of concern regarding acute stroke care and thrombolysis, modifications to the dialysis prescription and what adjuvant pharmacotherapy clinicians supported (for questionnaire structure, see online suppl. material; for all online suppl. material, see www.karger.com/doi/10.1159/000357155).
In the domains where some responses were incomplete, the denominator is given in the text. Descriptive statistics were expressed as the mean ± standard deviation and the median with interquartile range as appropriate. Continuous and categorical variables were compared using Student's t test and the χ 2 or MannWhitney U test, respectively, as appropriate. All analyses were performed using STATA 12.1 (www.stata.com). Statistical significance was defined by p < 0.05.
Results
Of the 433 clinicians who were invited, 122 (28%) from 55 centres responded. 69% of the respondents had >15 years' practice at the consultant level ( fig. 1 ) with 97% providing inpatient cover. The median size of the dialysis programme in each centre was 450 patients (73-1,450) with PD patients accounting for 16.0 ± 9.6% of the total cohort size on average. 23% of the respondents had dialysis patients in their centres who received stroke thrombolysis. The overall centre experience varied from 0 to 10 patients reflecting the dialysis programme size ( fig. 2 ). Only 10% were actually involved in thrombolysis decisions, and yet 75% reported a wish for some involvement in the process, with 82% wanting contact immediately prior to thrombolysis. The reasons cited included concerns about the risks of thrombolysis weighed against uncertainties about the benefits of this treatment in a particularly comorbid subgroup.
Key Concerns about Stroke Thrombolysis in Dialysis Patients
Concerns regarding the risk of bleeding with thrombolytic therapy predominated with a significantly higher risk perceived in HD patients as compared to those on PD (score of 7/10 vs. 6/10) applicable to intracranial and extracranial bleeding events ( table 1 ) . A high bleeding risk with thrombolysis (rated ≥ 7/10) was attributed to HD pa- Clinicians reported a moderate degree of concern regarding the impact of dialysis on cardiovascular stability around the time of thrombolysis. There was no significant difference according to the dialysis modality used ( table 1 ) . Similarly a moderate degree of concern was expressed regarding the perceived efficacy of this treatment as well as issues relating to drug dosing of dialysis patients by stroke teams rather than nephrologists ( table 1 ) with no significant differences between HD and PD patients. There was however an increased level of concern regarding the logistics of delivering HD compared to PD following thrombolysis (p = 0.001).
On average a moderate degree of concern (6/10) was raised regarding the available evidence base supporting the use of thrombolytic therapy for acute stroke in dialysis patients which did not vary according to dialysis modality. 
Modification of the Dialysis Prescription in Acute

Impact of Dialysis Therapy on Rehabilitation after Acute Stroke
The majority of respondents felt that the dialysis schedule impacted negatively on rehabilitation. This was more marked for HD patients (85%) compared to those on PD (64%, p = 0.001).
The adverse effect of HD on rehabilitation was attributed to issues such as: in PD patients with atrial fibrillation than in HD (79 vs. 66%, p = 0.04). This mainly related to bleeding risks associated with warfarin, and a number of clinicians favoured risk stratification using clinical scores (e.g. HAS-BLED, CHA2DS2-VASc) with individualised treatment decisions based on comorbidity.
Concluding Comments
Overall 76% of the respondents expressed a wish to participate in national studies examining clinical outcomes following stroke thrombolysis. There was no suggestion of conducting a stroke trial comparing thrombolysis to non-thrombolytic care. A number of respondents identified research areas of priority such as trials of warfarin versus antiplatelet therapy alone for stroke prevention in ESRD patients with atrial fibrillation, and on intracerebral haemorrhage in dialysis patients.
Discussion
Stroke thrombolysis in ESRD is dominated by concerns regarding bleeding risks and subsequent access to effective rehabilitation. Concerns regarding bleeding resonate with those of stroke physicians and remain an enduring treatment dilemma [7] . Higher bleeding rates with declining renal function in primary thrombolysis for myocardial infarction have been reported in a Swedish registry study but it is unclear whether this is an effect of treatment choice or renal dysfunction per se [8] . The absence of trial data on the safety of thrombolysis in ESRD was reinforced as a significant issue in our study. Previously 78% of stroke experts favoured intraarterial approaches rather than systemic thrombolysis in HD [7] .
We found a moderate degree of concern regarding the efficacy of thrombolysis in dialysis patients relating to a subjective appraisal of comorbid burden and baseline functional level rather than issues with the lytic efficacy of alteplase in ESRD. Patients with ESRD form compact blood clots in vitro that are more resistant to lysis [9] , but it is unclear whether this results in clinically significant effects in stroke thrombolysis. Furthermore dialysis patients have a high prevalence of clinically silent structural brain disease (e.g. infarcts, microbleeds) which may attenuate the thrombolytic benefit [10] [11] [12] , in keeping with data suggesting that impaired kidney function is an independent risk factor for suboptimal post-thrombolysis outcomes [13] [14] [15] .
Dialysis requires specialist nursing input, dedicated equipment and, in the case of in-centre HD, a dedicated clinical environment. Stroke thrombolysis is delivered in hyperacute stroke units in the UK under the direction of specialist teams. As a result acute stroke care and rehabilitation can be geographically separate from dialysis facilities. This dichotomy of care at a critical point in the patient pathway was highlighted as a major barrier to rehabilitation, especially for HD patients who require a higher level of technological and nursing support compared to those on PD. To date there are no published studies on rehabilitation outcomes following stroke in ESRD patients. Minimizing the time to recovery from HD therapy may improve engagement with rehabilitation services [16] , and co-ordinating dialysis treatments around rehabilitation may represent a simple, high-impact intervention. The integration of care remains challenging, and to date only 1 renal centre in the UK has a stroke unit embedded in its nephrology wards.
We found a striking disparity in the proportion of clinicians who tailor the dialysis prescription after acute stroke according to modality. Published recommendations for HD patients after acute brain injury derive in part from data obtained in traumatic brain injury which may not be applicable to stroke [17] . Similar recommen- 171 dations in PD are lacking, and there are no studies to date examining the acute impact of HD or PD on the brain of acute stroke patients. Despite appreciating platelet dysfunction in ESRD most UK nephrologists initiated or incremented antiplatelet therapies early after thrombolysis. The role of warfarin for stroke thromboprophylaxis in dialysis patients with atrial fibrillation remains contentious. Observational data in HD has linked warfarin use with a higher stroke risk in some studies [18] , whereas a recent study suggested the opposite [19] . Nonetheless, warfarin conferred a higher bleeding risk in that series in keeping with prior data [20, 21] . Furthermore data suggests that warfarin can increase the cardiovascular risk directly by accelerated vascular calcification [22] .
Our study constitutes the first appraisal of issues around stroke thrombolysis in dialysis reflecting topical concerns, therapeutic barriers and practical approaches to the management of patients. Our study is limited by a relatively low response rate despite parity with survey response rates in the literature [23] . Therefore our data may be prone to occult bias. In addition nephrologists with longer tenure in post were likely overrepresented in this study given that around 36% of the nephrologists in the UK have >15 years of consultant experience compared to 69% in this survey (p < 0.001). As a result, our findings could be vulnerable to confounding by deriving from a distinct, self-selected group of clinicians who nonetheless bring a wealth of clinical experience and are more likely to influence other professional opinions. A clustering of responses particularly from large urban centres (e.g. London and Glasgow) may have influenced our results further and curb the generalizability of our findings. Finally this study represents an assessment of specialist opinion which is not a substitute for clinical trial data.
There is enduring concern regarding systemic thrombolysis in dialysis cohorts that appear prejudiced with respect to their rehabilitation. We believe that large collaborative studies are needed to determine the safety of this therapy in dialysis patients and the optimal care pathways to ensure the best post-stroke outcomes. The efficacy and safety of warfarin in stroke thromboprophylaxis remains contentious, especially in HD patients, and trials are required to determine the risks and benefits of this agent in ESRD.
